Introduction Sonablate Corp. specializes in creating and manufacturing high intensity focused ultrasound surgical ablation systems. Their products include the Sonablate 450, which is designed for minimally invasive prostate cancer treatment, the Sonablate 500 for treating localized prostate cancer with reduced side effects, and the Sonatherm, which utilizes a laparoscopic probe to deliver robotic ablative therapy to soft tissue. The company was established in 2004 by Stephen R. Puckett Sr. and George M. Suarez and is based in Charlotte, North Carolina. |
Target- |
Mechanism Stem cell replacements |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date11 Sep 2024 |
Sponsor / Collaborator |
Start Date11 Jul 2019 |
Sponsor / Collaborator |
Start Date03 Jun 2015 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Autologous adipose derived MSCs therapy(Arkansas Heart Hospital) | Peripheral arterial occlusive disease More | Pending |